Note: Ingredients listed on restricted chemical lists
EC/CAS
63-42-3
Name of the chemical
Lactose C12H22O11
Concentration
N/A
EC/CAS
9004-65-3
Name of the chemical
methylhydroxypropylcellulose
Concentration
N/A
EC/CAS
25322-68-3
Name of the chemical
polyethyleneglycol
Concentration
N/A
EC/CAS
9003-39-8
Name of the chemical
polyvinylpyrrolidone
Concentration
N/A
General Information
Version
02
Revision date
2015-05-28
Product name
Anastrazole Tablets
Chemical name
1 ,3-Benzenediacetonitrile, a, a, a", a"-tetramethyl-5-( I H-1 ,2,4-triazol-1-ylmethyl)
1.2.1 Relevant identified uses
Therapeutic Category Non-steroidal aromatase inhibitor
1.2.2. Uses advised against
Contraindications
Emergency telephone
+91 79 6868100
Icons in SDS
Company Information
company name
Cadila Healthcare Ltd.
Section 2
Teratogenic Effects
Comments Anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. Anastrozole tablets is contraindicated in women who are or may become pregnant. In animal studies, anastrozole caused pregnancy failure, increased pregnancy loss, and signs of delayed fetal development. There are no studies of anastrozole tablets use in pregnant women. If anastrozole tablet is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus and potential risk for pregnancy loss. Nursing Mothers: It is not known if anastrozole is excreted in human milk. Because many drugs are excreted in human milk and because of the tumorigenicity shown for anastrozole in animal studies, or the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother Pregnancy Category X
